Clofarabine (Boyen)

氯法拉滨（博研医药）

Report date: 2025/12/22 17:31:31

Base Information

Drug NameClofarabine (Boyen)
Drug Alias NameBY-101
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionRibonucleotide reductase inhibitorsDNA polymerase alpha subunit inhibitors
TargetsDNA polymerase alpha subunitRibonucleotide reductase
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwan
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoyen Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBoyen Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A